Quantinno Capital Management LP Purchases 8,258 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Quantinno Capital Management LP increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,850 shares of the biopharmaceutical company’s stock after acquiring an additional 8,258 shares during the period. Quantinno Capital Management LP’s holdings in Alnylam Pharmaceuticals were worth $11,200,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. iA Global Asset Management Inc. grew its position in Alnylam Pharmaceuticals by 979.5% during the fourth quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares during the period. Hussman Strategic Advisors Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $2,505,000. GF Fund Management CO. LTD. raised its position in Alnylam Pharmaceuticals by 989.1% in the fourth quarter. GF Fund Management CO. LTD. now owns 30,462 shares of the biopharmaceutical company’s stock worth $12,113,000 after acquiring an additional 27,665 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Alnylam Pharmaceuticals by 22.6% during the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after acquiring an additional 16,503 shares during the last quarter. Finally, Brighton Jones LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $220.33 on Tuesday. The business’s 50-day simple moving average is $286.42 and its two-hundred day simple moving average is $309.85. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The stock has a market cap of $29.48 billion, a PE ratio of 40.95 and a beta of 0.30. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Raymond James upgraded Alnylam to “strong buy” and set a $420 price target, implying substantial potential upside from the referenced share price. The bullish call provides support for the stock despite its recent decline from prior highs. Raymond James upgrade
• Positive Sentiment: Chardan Capital reiterated its buy rating, reinforcing the view among some analysts that Alnylam’s growth prospects remain attractive. Chardan Capital buy rating
• Neutral Sentiment: Several firms reduced their price targets but maintained bullish ratings. Barclays lowered its target to $450 while keeping an “overweight” rating; Citigroup cut its target to $340 but retained a “buy” rating. Wells Fargo, Stifel and RBC also reduced targets to $316, $318 and $350, respectively. The cuts suggest more cautious valuation assumptions, although the ratings and targets remain positive. Analyst price-target changes Wells Fargo price target
• Neutral Sentiment: Other analysts have become more cautious. Morgan Stanley lowered its expectations, Oppenheimer issued a pessimistic forecast, and Wall Street Zen downgraded the stock to “hold.” These actions add pressure to the broader analyst outlook, which is mixed despite several high price targets. Morgan Stanley outlook
• Negative Sentiment: Two law firms announced continuing investigations into possible securities-law violations involving Alnylam. The notices invite shareholders who experienced losses to contact the firms. Although these announcements do not establish wrongdoing, they create potential legal, reputational and financial risks for ALNY. Frank R. Cruz investigation SBS Law investigation

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ALNY shares. Wells Fargo & Company reduced their price objective on Alnylam Pharmaceuticals from $377.00 to $316.00 and set an “equal weight” rating for the company in a research note on Friday. JPMorgan Chase & Co. cut their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday. Royal Bank Of Canada reduced their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday. Finally, Oppenheimer lowered their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $402.67.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.